Lauren Elizabeth Merz, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukocyte Count | 5 | 2024 | 1609 | 1.550 |
Why?
|
Pregnancy Complications, Hematologic | 2 | 2024 | 184 | 1.540 |
Why?
|
Neutrophils | 5 | 2024 | 3786 | 1.440 |
Why?
|
Neutropenia | 3 | 2023 | 892 | 0.820 |
Why?
|
von Willebrand Diseases | 1 | 2024 | 135 | 0.810 |
Why?
|
Thrombophilia | 1 | 2024 | 308 | 0.770 |
Why?
|
Thrombosis | 4 | 2024 | 2957 | 0.740 |
Why?
|
Sickle Cell Trait | 1 | 2021 | 86 | 0.730 |
Why?
|
Venous Thromboembolism | 2 | 2024 | 1883 | 0.700 |
Why?
|
Hematology | 1 | 2024 | 243 | 0.700 |
Why?
|
Anticoagulants | 3 | 2024 | 4852 | 0.690 |
Why?
|
Iliac Artery | 1 | 2020 | 344 | 0.630 |
Why?
|
Anemia, Iron-Deficiency | 1 | 2023 | 372 | 0.620 |
Why?
|
Anemia, Sickle Cell | 2 | 2024 | 1065 | 0.620 |
Why?
|
Drug Hypersensitivity | 2 | 2024 | 923 | 0.600 |
Why?
|
Communicable Diseases, Emerging | 2 | 2016 | 149 | 0.560 |
Why?
|
Leg | 1 | 2020 | 1088 | 0.490 |
Why?
|
Hypersensitivity | 1 | 2023 | 1172 | 0.460 |
Why?
|
Duffy Blood-Group System | 3 | 2024 | 61 | 0.440 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 1437 | 0.430 |
Why?
|
Transients and Migrants | 1 | 2016 | 170 | 0.430 |
Why?
|
Patient Care Team | 1 | 2024 | 2523 | 0.410 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2024 | 2763 | 0.390 |
Why?
|
Heart Diseases | 1 | 2024 | 2819 | 0.370 |
Why?
|
Penicillins | 2 | 2024 | 406 | 0.360 |
Why?
|
Pregnancy Complications | 1 | 2023 | 2973 | 0.320 |
Why?
|
Hematopoietic Stem Cell Transplantation | 2 | 2024 | 5717 | 0.310 |
Why?
|
Reference Values | 2 | 2023 | 4938 | 0.240 |
Why?
|
Abortion, Habitual | 1 | 2024 | 63 | 0.230 |
Why?
|
Skin Neoplasms | 1 | 2023 | 5863 | 0.230 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2019 | 3626 | 0.220 |
Why?
|
General Practice | 1 | 2024 | 101 | 0.210 |
Why?
|
Antiphospholipid Syndrome | 1 | 2024 | 167 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3115 | 0.200 |
Why?
|
Amoxicillin | 1 | 2023 | 182 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3238 | 0.200 |
Why?
|
Patient Acceptance of Health Care | 1 | 2016 | 3231 | 0.200 |
Why?
|
beta-Lactams | 1 | 2023 | 158 | 0.200 |
Why?
|
Skin Tests | 1 | 2023 | 639 | 0.190 |
Why?
|
Administration, Cutaneous | 1 | 2023 | 716 | 0.190 |
Why?
|
Peroxiredoxins | 1 | 2020 | 51 | 0.170 |
Why?
|
Catalase | 1 | 2020 | 215 | 0.170 |
Why?
|
Humans | 29 | 2024 | 768166 | 0.170 |
Why?
|
Pregnancy Complications, Cardiovascular | 1 | 2024 | 519 | 0.170 |
Why?
|
Switzerland | 2 | 2021 | 323 | 0.170 |
Why?
|
Quadriceps Muscle | 1 | 2020 | 157 | 0.160 |
Why?
|
Isoniazid | 1 | 2020 | 288 | 0.150 |
Why?
|
Africa South of the Sahara | 1 | 2021 | 752 | 0.150 |
Why?
|
Intestinal Diseases | 1 | 2022 | 505 | 0.140 |
Why?
|
Muscular Dystrophy, Duchenne | 1 | 2020 | 271 | 0.140 |
Why?
|
Postpartum Period | 1 | 2024 | 1198 | 0.140 |
Why?
|
Blood Coagulation | 1 | 2023 | 1162 | 0.140 |
Why?
|
Arginine | 1 | 2020 | 932 | 0.130 |
Why?
|
Borrelia Infections | 1 | 2016 | 17 | 0.130 |
Why?
|
Leukocidins | 1 | 2016 | 18 | 0.130 |
Why?
|
Diphtheria | 1 | 2016 | 32 | 0.130 |
Why?
|
Morbidity | 1 | 2021 | 1755 | 0.130 |
Why?
|
Exotoxins | 1 | 2016 | 123 | 0.130 |
Why?
|
Hygiene | 1 | 2016 | 95 | 0.130 |
Why?
|
Thrombectomy | 1 | 2020 | 676 | 0.120 |
Why?
|
Exercise Tolerance | 1 | 2020 | 846 | 0.120 |
Why?
|
Angiography | 1 | 2020 | 1597 | 0.120 |
Why?
|
Epidemics | 1 | 2021 | 517 | 0.120 |
Why?
|
Iron | 1 | 2023 | 1813 | 0.120 |
Why?
|
Pandemics | 4 | 2023 | 8748 | 0.120 |
Why?
|
Female | 14 | 2024 | 397192 | 0.110 |
Why?
|
Coronary Circulation | 1 | 2020 | 1617 | 0.110 |
Why?
|
Heterozygote | 1 | 2020 | 2798 | 0.110 |
Why?
|
DNA, Viral | 1 | 2020 | 2204 | 0.110 |
Why?
|
Neoplasms | 2 | 2024 | 22371 | 0.100 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2020 | 944 | 0.100 |
Why?
|
Pregnancy | 2 | 2024 | 30256 | 0.100 |
Why?
|
Cross Infection | 1 | 2021 | 1426 | 0.100 |
Why?
|
Influenza, Human | 2 | 2021 | 1541 | 0.090 |
Why?
|
Adult | 9 | 2024 | 223646 | 0.090 |
Why?
|
Bacterial Toxins | 1 | 2016 | 922 | 0.090 |
Why?
|
Aged | 7 | 2024 | 171504 | 0.090 |
Why?
|
HIV Infections | 1 | 2016 | 17569 | 0.080 |
Why?
|
Mycobacterium tuberculosis | 1 | 2020 | 1930 | 0.080 |
Why?
|
Quality Improvement | 1 | 2024 | 3857 | 0.080 |
Why?
|
Quality of Life | 2 | 2021 | 13490 | 0.080 |
Why?
|
Internship and Residency | 2 | 2024 | 5953 | 0.080 |
Why?
|
Sepsis | 1 | 2022 | 2608 | 0.080 |
Why?
|
Clinical Competence | 1 | 2024 | 4858 | 0.070 |
Why?
|
Cardiomyopathies | 1 | 2020 | 2056 | 0.070 |
Why?
|
Male | 10 | 2024 | 364719 | 0.070 |
Why?
|
Myocardium | 1 | 2020 | 4788 | 0.070 |
Why?
|
Staphylococcal Infections | 1 | 2016 | 1398 | 0.070 |
Why?
|
Bacterial Proteins | 1 | 2020 | 3840 | 0.070 |
Why?
|
Health Personnel | 1 | 2019 | 3385 | 0.060 |
Why?
|
Middle Aged | 6 | 2024 | 223492 | 0.060 |
Why?
|
Phenotype | 1 | 2023 | 16726 | 0.060 |
Why?
|
Telemedicine | 1 | 2023 | 3109 | 0.060 |
Why?
|
Anxiety | 1 | 2019 | 4672 | 0.060 |
Why?
|
Internal Medicine | 1 | 2011 | 1064 | 0.050 |
Why?
|
Risk Assessment | 1 | 2024 | 24315 | 0.050 |
Why?
|
Child | 4 | 2023 | 80917 | 0.050 |
Why?
|
United States | 4 | 2024 | 73039 | 0.050 |
Why?
|
Eligibility Determination | 1 | 2024 | 421 | 0.040 |
Why?
|
Mice, Inbred mdx | 1 | 2020 | 90 | 0.040 |
Why?
|
Retrospective Studies | 4 | 2024 | 81762 | 0.040 |
Why?
|
Amidohydrolases | 1 | 2020 | 160 | 0.040 |
Why?
|
Prevalence | 1 | 2016 | 15869 | 0.040 |
Why?
|
Prognosis | 1 | 2019 | 30010 | 0.040 |
Why?
|
Mutation | 2 | 2020 | 30238 | 0.040 |
Why?
|
Demography | 1 | 2023 | 1641 | 0.040 |
Why?
|
Risk Factors | 1 | 2024 | 74944 | 0.040 |
Why?
|
Cohort Studies | 1 | 2019 | 41754 | 0.030 |
Why?
|
Genes, Bacterial | 1 | 2020 | 1076 | 0.030 |
Why?
|
Tetrazoles | 1 | 2022 | 923 | 0.030 |
Why?
|
Imidazoles | 1 | 2022 | 1169 | 0.030 |
Why?
|
Necrosis | 1 | 2020 | 1616 | 0.030 |
Why?
|
Diarrhea | 1 | 2022 | 1320 | 0.030 |
Why?
|
DNA, Bacterial | 1 | 2020 | 1478 | 0.030 |
Why?
|
Seasons | 1 | 2021 | 1524 | 0.030 |
Why?
|
Aged, 80 and over | 1 | 2019 | 59629 | 0.030 |
Why?
|
Microbial Sensitivity Tests | 1 | 2020 | 1967 | 0.030 |
Why?
|
Fatigue | 1 | 2021 | 1557 | 0.030 |
Why?
|
Inpatients | 1 | 2024 | 2566 | 0.030 |
Why?
|
Drug Contamination | 1 | 2014 | 151 | 0.030 |
Why?
|
Prospective Studies | 1 | 2016 | 54926 | 0.020 |
Why?
|
Antitubercular Agents | 1 | 2020 | 1397 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2020 | 2744 | 0.020 |
Why?
|
Drug Resistance, Microbial | 1 | 2014 | 830 | 0.020 |
Why?
|
Mycoses | 1 | 2014 | 386 | 0.020 |
Why?
|
Critical Illness | 1 | 2022 | 2756 | 0.020 |
Why?
|
Gonorrhea | 1 | 2014 | 355 | 0.020 |
Why?
|
Pain | 1 | 2024 | 5100 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2022 | 3800 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2020 | 5797 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2024 | 8054 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2020 | 9561 | 0.020 |
Why?
|
China | 1 | 2014 | 2395 | 0.020 |
Why?
|
Ventricular Function, Left | 1 | 2020 | 3941 | 0.020 |
Why?
|
Hospitals | 1 | 2021 | 3886 | 0.020 |
Why?
|
Tuberculosis | 1 | 2020 | 2029 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2024 | 7477 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2023 | 5520 | 0.020 |
Why?
|
Registries | 1 | 2020 | 8375 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2024 | 26379 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2020 | 22379 | 0.010 |
Why?
|
Antineoplastic Agents | 1 | 2024 | 13676 | 0.010 |
Why?
|
Depression | 1 | 2021 | 8230 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2020 | 18349 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2020 | 26422 | 0.010 |
Why?
|
Infant | 1 | 2020 | 36535 | 0.010 |
Why?
|
Child, Preschool | 1 | 2020 | 42669 | 0.010 |
Why?
|
Adolescent | 1 | 2020 | 89169 | 0.010 |
Why?
|
Animals | 1 | 2020 | 169246 | 0.000 |
Why?
|